Work

MHC class II and CD80 tumor cell?based vaccines are potent activators of type 1 CD4 + T lymphocytes provided they do not coexpress invariant chain

Year: 2004

Type: article

Source: Cancer Immunology Immunotherapy

DOI: 10.1007/s00262-003-0486-4

Authors: Dan Ilkovitch, Suzanne Ostrand-Rosenberg

Institution: University of Maryland, Baltimore County

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Cell-based tumor vaccines targeting CD4+ T lymphocytes, G4251832300, G5710394907, G6596207287

OpenAlex ID: W2014249366

FWCI: 0.833

Cites: 48

Cited by: 12

Related to: 10